Objective To evaluate the efficacy of tirilizumab in patients undergoing surgery for non-small cell lung cancer treated with platinum-containing two-agent chemotherapy.Methods One hundred patients with non-small cell lung cancer who underwent surgical treatment from January 2022 to December 2023 were selected and randomly divided into two groups according to the random number table method.Fifty patients in the control group were treated with platinum-based doublet chemotherapy before surgery,while fifty patients in the observation one with tislelizumab in addition to the control group treatment.The clinical efficacy,event-free survival,disease-free survival,quality of life improvement,and toxic and side effects were compared between the two groups.Results The clinical efficacy(complete remission rate:20.00%vs.10.00%)and pathological evaluation(major pathological response rate:46.00%vs.20.00%)of the observation group were better than those of the control(Z=3.484,P<0.001;χ2=7.664,P=0.006).Kaplan-Meier survival analysis showed that the event-free survival rate(84.00%vs.60.00%)and disease-free survival rate(78.00%vs.60.00%)in the observation group were higher than those in the control(χ2=4.298,P=0.038;χ2=4.783,P=0.029).In terms of quality of life improvement rate,the observation group(64.00%)was higher than the control(42.00%),and the difference was statistically significant(χ2=4.857,P=0.028).There was no statistically significant difference in the incidence of toxic and side effects between the two groups(18.00%vs.22.00%)(χ2=0.250,P=0.617).Conclusion The implementation of tirilizumab in patients undergoing surgery for NSCLC treated with platinum-containing dual-agent chemotherapy can improve the therapeutic efficacy,promote the improvement of the quality of life but does not increase the risk of the occurrence of toxic side effects in patients.
Non-small cell lung cancerTirelizumabPlatinum containing dual drugClinical efficacyToxic side effect
NETL
NSTL
万方数据
